Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits

James E. Robinson, Kathryn M. Hastie, Robert Cross, Rachael E. Yenni, Deborah H. Elliott, Julie A. Rouelle, Chandrika B. Kannadka, Ashley A. Smira, Courtney E. Garry, Benjamin T. Bradley, Haini Yu, Jeffrey G. Shaffer, Matt L. Boisen, Jessica N. Hartnett, Michelle A. Zandonatti, Megan M. Rowland, Megan L. Heinrich, Luis Martinez-Sobrido, Benson Cheng, Juan C. De La TorreKristian G. Andersen, Augustine Goba, Mambu Momoh, Mohamed Fullah, Michael Gbakie, Lansana Kanneh, Veronica J. Koroma, Richard Fonnie, Simbirie C. Jalloh, Brima Kargbo, Mohamed A. Vandi, Momoh Gbetuwa, Odia Ikponmwosa, Danny A. Asogun, Peter O. Okokhere, Onikepe A. Follarin, John S. Schieffelin, Kelly R. Pitts, Joan B. Geisbert, Peter C. Kulakoski, Russell B. Wilson, Christian T. Happi, Pardis C. Sabeti, Sahr M. Gevao, S. Humarr Khan, Donald S. Grant, Thomas Geisbert, Erica Ollmann Saphire, Luis M. Branco, Robert F. Garry

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Lassa fever is a severe multisystem disease that often has haemorrhagic manifestations. The epitopes of the Lassa virus (LASV) surface glycoproteins recognized by naturally infected human hosts have not been identified or characterized. Here we have cloned 113 human monoclonal antibodies (mAbs) specific for LASV glycoproteins from memory B cells of Lassa fever survivors from West Africa. One-half bind the GP2 fusion subunit, one-fourth recognize the GP1 receptor-binding subunit and the remaining fourth are specific for the assembled glycoprotein complex, requiring both GP1 and GP2 subunits for recognition. Notably, of the 16 mAbs that neutralize LASV, 13 require the assembled glycoprotein complex for binding, while the remaining 3 require GP1 only. Compared with non-neutralizing mAbs, neutralizing mAbs have higher binding affinities and greater divergence from germline progenitors. Some mAbs potently neutralize all four LASV lineages. These insights from LASV human mAb characterization will guide strategies for immunotherapeutic development and vaccine design.

Original languageEnglish (US)
Article number11544
JournalNature Communications
Volume7
DOIs
StatePublished - May 10 2016

Fingerprint

Lassa virus
viruses
antibodies
Viruses
Epitopes
Glycoproteins
Monoclonal Antibodies
Lassa Fever
fever
vaccines
Western Africa
Membrane Glycoproteins
Neutralizing Antibodies
affinity
divergence
B-Lymphocytes
Fusion reactions
Vaccines
fusion
Cells

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Chemistry(all)
  • Physics and Astronomy(all)

Cite this

Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. / Robinson, James E.; Hastie, Kathryn M.; Cross, Robert; Yenni, Rachael E.; Elliott, Deborah H.; Rouelle, Julie A.; Kannadka, Chandrika B.; Smira, Ashley A.; Garry, Courtney E.; Bradley, Benjamin T.; Yu, Haini; Shaffer, Jeffrey G.; Boisen, Matt L.; Hartnett, Jessica N.; Zandonatti, Michelle A.; Rowland, Megan M.; Heinrich, Megan L.; Martinez-Sobrido, Luis; Cheng, Benson; De La Torre, Juan C.; Andersen, Kristian G.; Goba, Augustine; Momoh, Mambu; Fullah, Mohamed; Gbakie, Michael; Kanneh, Lansana; Koroma, Veronica J.; Fonnie, Richard; Jalloh, Simbirie C.; Kargbo, Brima; Vandi, Mohamed A.; Gbetuwa, Momoh; Ikponmwosa, Odia; Asogun, Danny A.; Okokhere, Peter O.; Follarin, Onikepe A.; Schieffelin, John S.; Pitts, Kelly R.; Geisbert, Joan B.; Kulakoski, Peter C.; Wilson, Russell B.; Happi, Christian T.; Sabeti, Pardis C.; Gevao, Sahr M.; Khan, S. Humarr; Grant, Donald S.; Geisbert, Thomas; Saphire, Erica Ollmann; Branco, Luis M.; Garry, Robert F.

In: Nature Communications, Vol. 7, 11544, 10.05.2016.

Research output: Contribution to journalArticle

Robinson, JE, Hastie, KM, Cross, R, Yenni, RE, Elliott, DH, Rouelle, JA, Kannadka, CB, Smira, AA, Garry, CE, Bradley, BT, Yu, H, Shaffer, JG, Boisen, ML, Hartnett, JN, Zandonatti, MA, Rowland, MM, Heinrich, ML, Martinez-Sobrido, L, Cheng, B, De La Torre, JC, Andersen, KG, Goba, A, Momoh, M, Fullah, M, Gbakie, M, Kanneh, L, Koroma, VJ, Fonnie, R, Jalloh, SC, Kargbo, B, Vandi, MA, Gbetuwa, M, Ikponmwosa, O, Asogun, DA, Okokhere, PO, Follarin, OA, Schieffelin, JS, Pitts, KR, Geisbert, JB, Kulakoski, PC, Wilson, RB, Happi, CT, Sabeti, PC, Gevao, SM, Khan, SH, Grant, DS, Geisbert, T, Saphire, EO, Branco, LM & Garry, RF 2016, 'Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits', Nature Communications, vol. 7, 11544. https://doi.org/10.1038/ncomms11544
Robinson, James E. ; Hastie, Kathryn M. ; Cross, Robert ; Yenni, Rachael E. ; Elliott, Deborah H. ; Rouelle, Julie A. ; Kannadka, Chandrika B. ; Smira, Ashley A. ; Garry, Courtney E. ; Bradley, Benjamin T. ; Yu, Haini ; Shaffer, Jeffrey G. ; Boisen, Matt L. ; Hartnett, Jessica N. ; Zandonatti, Michelle A. ; Rowland, Megan M. ; Heinrich, Megan L. ; Martinez-Sobrido, Luis ; Cheng, Benson ; De La Torre, Juan C. ; Andersen, Kristian G. ; Goba, Augustine ; Momoh, Mambu ; Fullah, Mohamed ; Gbakie, Michael ; Kanneh, Lansana ; Koroma, Veronica J. ; Fonnie, Richard ; Jalloh, Simbirie C. ; Kargbo, Brima ; Vandi, Mohamed A. ; Gbetuwa, Momoh ; Ikponmwosa, Odia ; Asogun, Danny A. ; Okokhere, Peter O. ; Follarin, Onikepe A. ; Schieffelin, John S. ; Pitts, Kelly R. ; Geisbert, Joan B. ; Kulakoski, Peter C. ; Wilson, Russell B. ; Happi, Christian T. ; Sabeti, Pardis C. ; Gevao, Sahr M. ; Khan, S. Humarr ; Grant, Donald S. ; Geisbert, Thomas ; Saphire, Erica Ollmann ; Branco, Luis M. ; Garry, Robert F. / Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. In: Nature Communications. 2016 ; Vol. 7.
@article{6893bcf2829b4e6398d0a7acf814cc91,
title = "Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits",
abstract = "Lassa fever is a severe multisystem disease that often has haemorrhagic manifestations. The epitopes of the Lassa virus (LASV) surface glycoproteins recognized by naturally infected human hosts have not been identified or characterized. Here we have cloned 113 human monoclonal antibodies (mAbs) specific for LASV glycoproteins from memory B cells of Lassa fever survivors from West Africa. One-half bind the GP2 fusion subunit, one-fourth recognize the GP1 receptor-binding subunit and the remaining fourth are specific for the assembled glycoprotein complex, requiring both GP1 and GP2 subunits for recognition. Notably, of the 16 mAbs that neutralize LASV, 13 require the assembled glycoprotein complex for binding, while the remaining 3 require GP1 only. Compared with non-neutralizing mAbs, neutralizing mAbs have higher binding affinities and greater divergence from germline progenitors. Some mAbs potently neutralize all four LASV lineages. These insights from LASV human mAb characterization will guide strategies for immunotherapeutic development and vaccine design.",
author = "Robinson, {James E.} and Hastie, {Kathryn M.} and Robert Cross and Yenni, {Rachael E.} and Elliott, {Deborah H.} and Rouelle, {Julie A.} and Kannadka, {Chandrika B.} and Smira, {Ashley A.} and Garry, {Courtney E.} and Bradley, {Benjamin T.} and Haini Yu and Shaffer, {Jeffrey G.} and Boisen, {Matt L.} and Hartnett, {Jessica N.} and Zandonatti, {Michelle A.} and Rowland, {Megan M.} and Heinrich, {Megan L.} and Luis Martinez-Sobrido and Benson Cheng and {De La Torre}, {Juan C.} and Andersen, {Kristian G.} and Augustine Goba and Mambu Momoh and Mohamed Fullah and Michael Gbakie and Lansana Kanneh and Koroma, {Veronica J.} and Richard Fonnie and Jalloh, {Simbirie C.} and Brima Kargbo and Vandi, {Mohamed A.} and Momoh Gbetuwa and Odia Ikponmwosa and Asogun, {Danny A.} and Okokhere, {Peter O.} and Follarin, {Onikepe A.} and Schieffelin, {John S.} and Pitts, {Kelly R.} and Geisbert, {Joan B.} and Kulakoski, {Peter C.} and Wilson, {Russell B.} and Happi, {Christian T.} and Sabeti, {Pardis C.} and Gevao, {Sahr M.} and Khan, {S. Humarr} and Grant, {Donald S.} and Thomas Geisbert and Saphire, {Erica Ollmann} and Branco, {Luis M.} and Garry, {Robert F.}",
year = "2016",
month = "5",
day = "10",
doi = "10.1038/ncomms11544",
language = "English (US)",
volume = "7",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits

AU - Robinson, James E.

AU - Hastie, Kathryn M.

AU - Cross, Robert

AU - Yenni, Rachael E.

AU - Elliott, Deborah H.

AU - Rouelle, Julie A.

AU - Kannadka, Chandrika B.

AU - Smira, Ashley A.

AU - Garry, Courtney E.

AU - Bradley, Benjamin T.

AU - Yu, Haini

AU - Shaffer, Jeffrey G.

AU - Boisen, Matt L.

AU - Hartnett, Jessica N.

AU - Zandonatti, Michelle A.

AU - Rowland, Megan M.

AU - Heinrich, Megan L.

AU - Martinez-Sobrido, Luis

AU - Cheng, Benson

AU - De La Torre, Juan C.

AU - Andersen, Kristian G.

AU - Goba, Augustine

AU - Momoh, Mambu

AU - Fullah, Mohamed

AU - Gbakie, Michael

AU - Kanneh, Lansana

AU - Koroma, Veronica J.

AU - Fonnie, Richard

AU - Jalloh, Simbirie C.

AU - Kargbo, Brima

AU - Vandi, Mohamed A.

AU - Gbetuwa, Momoh

AU - Ikponmwosa, Odia

AU - Asogun, Danny A.

AU - Okokhere, Peter O.

AU - Follarin, Onikepe A.

AU - Schieffelin, John S.

AU - Pitts, Kelly R.

AU - Geisbert, Joan B.

AU - Kulakoski, Peter C.

AU - Wilson, Russell B.

AU - Happi, Christian T.

AU - Sabeti, Pardis C.

AU - Gevao, Sahr M.

AU - Khan, S. Humarr

AU - Grant, Donald S.

AU - Geisbert, Thomas

AU - Saphire, Erica Ollmann

AU - Branco, Luis M.

AU - Garry, Robert F.

PY - 2016/5/10

Y1 - 2016/5/10

N2 - Lassa fever is a severe multisystem disease that often has haemorrhagic manifestations. The epitopes of the Lassa virus (LASV) surface glycoproteins recognized by naturally infected human hosts have not been identified or characterized. Here we have cloned 113 human monoclonal antibodies (mAbs) specific for LASV glycoproteins from memory B cells of Lassa fever survivors from West Africa. One-half bind the GP2 fusion subunit, one-fourth recognize the GP1 receptor-binding subunit and the remaining fourth are specific for the assembled glycoprotein complex, requiring both GP1 and GP2 subunits for recognition. Notably, of the 16 mAbs that neutralize LASV, 13 require the assembled glycoprotein complex for binding, while the remaining 3 require GP1 only. Compared with non-neutralizing mAbs, neutralizing mAbs have higher binding affinities and greater divergence from germline progenitors. Some mAbs potently neutralize all four LASV lineages. These insights from LASV human mAb characterization will guide strategies for immunotherapeutic development and vaccine design.

AB - Lassa fever is a severe multisystem disease that often has haemorrhagic manifestations. The epitopes of the Lassa virus (LASV) surface glycoproteins recognized by naturally infected human hosts have not been identified or characterized. Here we have cloned 113 human monoclonal antibodies (mAbs) specific for LASV glycoproteins from memory B cells of Lassa fever survivors from West Africa. One-half bind the GP2 fusion subunit, one-fourth recognize the GP1 receptor-binding subunit and the remaining fourth are specific for the assembled glycoprotein complex, requiring both GP1 and GP2 subunits for recognition. Notably, of the 16 mAbs that neutralize LASV, 13 require the assembled glycoprotein complex for binding, while the remaining 3 require GP1 only. Compared with non-neutralizing mAbs, neutralizing mAbs have higher binding affinities and greater divergence from germline progenitors. Some mAbs potently neutralize all four LASV lineages. These insights from LASV human mAb characterization will guide strategies for immunotherapeutic development and vaccine design.

UR - http://www.scopus.com/inward/record.url?scp=84968627164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84968627164&partnerID=8YFLogxK

U2 - 10.1038/ncomms11544

DO - 10.1038/ncomms11544

M3 - Article

C2 - 27161536

AN - SCOPUS:84968627164

VL - 7

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 11544

ER -